In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy ...

In this video interview, Michael Liu, medical student and researcher at Harvard Medical School, highlights key findings from ...

Welireg (belzutifan), an oral HIF-2α inhibitor, demonstrated an objective response rate of 26% in the LITESPARK-015 study. 1. Regulatory milestone for rare tumors: Merck’s Welireg received FDA ...

In the Phase II LUMINOSITY study, Emrelis (telisotuzumab vedotin-tllv), a first-in-class c-Met-directed antibody-drug ...

In this video interview, Michael Liu, medical student and researcher at Harvard Medical School, discusses a recent study he conducted on the characterization of research funding cuts.

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Don't miss IQVIA Technologies' webinar on clinical trial budgeting. Gain insights into effective budget-building techniques and explore how IQVIA GrantPlan can help you finalize budgets swiftly and ...

In February, the National Institutes of Health (NIH) announced a cut of “indirect expenses” in its funding for research ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...